The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM).
David H. Vesole
Consultant or Advisory Role - Celgene
Honoraria - Celgene; Onyx; Takeda
David Samuel DiCapua Siegel
Consultant or Advisory Role - Celgene; Merck Sharp & Dohme; Onyx; Takeda
Other Remuneration - Celgene; Onyx; Takeda
Joshua Ryan Richter
Honoraria - Celgene; Millennium; Onyx
Ann McNeill
Consultant or Advisory Role - Celgene; Millennium
Honoraria - Celgene; Millennium
Palka Anand
Honoraria - Onyx
Urszula Bednarz
No relevant relationships to disclose
Kristin Ivanovski
No relevant relationships to disclose
Laura McBride
Consultant or Advisory Role - Onyx
Honoraria - Celgene; Onyx
Laura Raucci
No relevant relationships to disclose
Veena Batra
No relevant relationships to disclose
Adolfo Aleman
No relevant relationships to disclose
Taliah Sims
No relevant relationships to disclose
Laura Guerrero
No relevant relationships to disclose
Judith Smith
No relevant relationships to disclose
Anthony R. Mato
Honoraria - Celgene
Research Funding - Celgene
Elizabeth Bilotti
Honoraria - Celgene; Onyx; Takeda